Photodynamic Therapy
PDT, as this bio-medical technology is known in the trade press and regular media, and it's second generation variant, are in use, in different stages of clinical trials, or under licensing examination.
PDT treatments are addressing head, lung, neck, cervical and bladder cancers, brain tumors, as well as rheumatism. Second-generation developments are being studied for treating age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
The technologies are approved for use in the following countries: